A Phase 1 Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104 in Subjects With Relapsed/Refractory Advanced or Metastatic Solid Tumors or Lymphomas
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 4
- 主要终点
- Number of participants with a Dose Limiting Toxicity (DLT)
研究概览
简要总结
This was a first-in-human, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 as monotherapy or in combination with AK104 in subjects with advanced or metastatic solid tumors.
详细描述
The study was conducted across 2 parts. Part A of the study was the dose escalation part of AK117 monotherapy as priming dose to evaluate the safety and tolerability of AK117 weekly dosing in solid tumors. Part B which was to evaluate the optimal maintenance dose of AK117 was not performed as the MAD dose level of AK117 monotherapy was determined in Part A.
Part A2 was the dose escalation part of AK117 in combination with AK104 to evaluate the safety and tolerability of AK117 monotherapy in solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to provide written and signed informed consent
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or
- •Life expectancy ≥12 weeks
- •Females of childbearing potential and non-sterilized males who are sexually active must use an effective method of contraception from screening until 120 days after final dose of investigational product or women of non-childbearing potential.
- •Willing to receive blood transfusion(s) when so advised by the investigator.
- •Adequate organ function.
- •Subjects must have a histologically or cytologically confirmed advanced solid tumor that is refractory or relapsed to the current standard therapies or which no effective standard therapy is available.
- •At least 1 measurable lesion according to RECIST v1.1
排除标准
- •Concurrent enrollment in another clinical study excluding observational trials
- •Prior malignancy active within the previous 3 years except for the tumor for which a subject is enrolled in the study
- •Active brain/central nervous system (CNS) metastases
- •Active infections requiring systemic therapy within 2 weeks prior to the first dose of investigational product.
- •Known history of HIV.
- •Known active hepatitis B or C infections
- •Active or prior documented autoimmune disease that may relapse.
- •History of interstitial lung disease or non-infectious pneumonitis, except those induced by radiation therapies.
- •History of defects in RBC production, or hemoglobin production or metabolism
- •Patients with clinically significant cardio-cerebrovascular disease.
- •History of severe hypersensitivity reactions to other mAbs.
- •History of organ transplantation.
- •Receiving any anticancer therapy targeting the CD47/SIRPα ; Anticancer small molecule targeted agent within 2 weeks prior to the first dose of the investigational product; Anticancer mAbs within 6 weeks prior to the first dose of investigational product or 5 half-lives (whichever is lesser); Other anticancer therapy within 4 weeks prior to the first dose of the investigational product;
- •Subjects with a condition requiring systemic treatment with either corticosteroid (>10 mg daily doses)) or other immunosuppressive medications within 2 weeks prior to the first dose of investigational product.
- •Received a live attenuated vaccine within 4 weeks prior to the first dose of investigational product.
研究组 & 干预措施
Treatment
Parts A and B: AK117 monotherapy intravenous (IV) infusion- weekly doses in a 28-day cycle.
Parts A2: AK117 (QW) + AK104 (Q3W) combination therapy intravenous (IV) infusion in a 21-day cycle.
干预措施: AK117 (Drug)
Treatment
Parts A and B: AK117 monotherapy intravenous (IV) infusion- weekly doses in a 28-day cycle.
Parts A2: AK117 (QW) + AK104 (Q3W) combination therapy intravenous (IV) infusion in a 21-day cycle.
干预措施: AK117+AK104 (Drug)
结局指标
主要结局
Number of participants with a Dose Limiting Toxicity (DLT)
时间窗: During the first 4 weeks of first treatment dose of AK117 as monotherapy or during the first 3 weeks of treatment dose of AK117+AK104 as combination therapy.
DLTs will be assessed during the first 4 weeks (AK117 monotherapy) or first 3 weeks (AK117+AK104 combination therapy) of treatment for dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment.
Incidence and nature of adverse events (AEs)
时间窗: From the time of informed consent signed through 30 days after the last dose of AK117 as monotherapy or in combination with AK104
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
次要结局
- Disease control rate (DCR)(Up to 2 years)
- Maximum observed concentration (Cmax) of AK117 as monotherapy or in combination with AK104 and Minimum observed concentration (Cmin) of AK117 at steady stateconcentration (Cmin) of AK117 at steady state(From first dose through to 30 days after last dose of investigational products.)
- Number of subjects who develop detectable anti-drug antibodies (ADAs) of AK117 as monotherapy or in combination with AK104(From first dose through to 30 days after last dose of investigational products.)
- Objective response rate (ORR)(Up to 2 years)
- Area under the curve (AUC) of AK117 as monotherapy or in combination with AK104 for assessment of pharmacokinetics(From first dose through to 30 days after last dose of investigational products.)
- Receptor occupancy (RO) of AK117 as monotherapy or in combination with AK104 to evaluate target engagement(From first dose through to 30 days after last dose of investigational products.)